Cargando…

Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation

INTRODUCTION: Giant cell arteritis (GCA) is an autoimmune disease commonest in Northern Europe and Scandinavia. Previous studies report various associations with HLA-DRB1*04 and HLA-DRB1*01; HLA-DRB1 alleles show a gradient in population prevalence within Europe. Our aims were (1) to determine which...

Descripción completa

Detalles Bibliográficos
Autores principales: Mackie, Sarah Louise, Taylor, John C., Haroon-Rashid, Lubna, Martin, Stephen, Dasgupta, Bhaskar, Gough, Andrew, Green, Michael, Hordon, Lesley, Jarrett, Stephen, Pease, Colin T., Barrett, Jennifer H., Watts, Richard, Morgan, Ann W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520081/
https://www.ncbi.nlm.nih.gov/pubmed/26223536
http://dx.doi.org/10.1186/s13075-015-0692-4
_version_ 1782383611829288960
author Mackie, Sarah Louise
Taylor, John C.
Haroon-Rashid, Lubna
Martin, Stephen
Dasgupta, Bhaskar
Gough, Andrew
Green, Michael
Hordon, Lesley
Jarrett, Stephen
Pease, Colin T.
Barrett, Jennifer H.
Watts, Richard
Morgan, Ann W.
author_facet Mackie, Sarah Louise
Taylor, John C.
Haroon-Rashid, Lubna
Martin, Stephen
Dasgupta, Bhaskar
Gough, Andrew
Green, Michael
Hordon, Lesley
Jarrett, Stephen
Pease, Colin T.
Barrett, Jennifer H.
Watts, Richard
Morgan, Ann W.
author_sort Mackie, Sarah Louise
collection PubMed
description INTRODUCTION: Giant cell arteritis (GCA) is an autoimmune disease commonest in Northern Europe and Scandinavia. Previous studies report various associations with HLA-DRB1*04 and HLA-DRB1*01; HLA-DRB1 alleles show a gradient in population prevalence within Europe. Our aims were (1) to determine which amino acid residues within HLA-DRB1 best explained HLA-DRB1 allele susceptibility and protective effects in GCA, seen in UK data combined in meta-analysis with previously published data, and (2) to determine whether the incidence of GCA in different countries is associated with the population prevalence of the HLA-DRB1 alleles that we identified in our meta-analysis. METHODS: GCA patients from the UK GCA Consortium were genotyped by using single-strand oligonucleotide polymerization, allele-specific polymerase chain reaction, and direct sequencing. Meta-analysis was used to compare and combine our results with published data, and public databases were used to identify amino acid residues that may explain observed susceptibility/protective effects. Finally, we determined the relationship of HLA-DRB1*04 population carrier frequency and latitude to GCA incidence reported in different countries. RESULTS: In our UK data (225 cases and 1378 controls), HLA-DRB1*04 carriage was associated with GCA susceptibility (odds ratio (OR) = 2.69, P = 1.5×10(−11)), but HLA-DRB1*01 was protective (adjusted OR = 0.55, P = 0.0046). In meta-analysis combined with 14 published studies (an additional 691 cases and 4038 controls), protective effects were seen from HLA-DR2, which comprises HLA-DRB1*15 and HLA-DRB1*16 (OR = 0.65, P = 8.2×10(−6)) and possibly from HLA-DRB1*01 (OR = 0.73, P = 0.037). GCA incidence (n = 17 countries) was associated with population HLA-DRB1*04 allele frequency (P = 0.008; adjusted R(2) = 0.51 on univariable analysis, adjusted R(2) = 0.62 after also including latitude); latitude also made an independent contribution. CONCLUSIONS: We confirm that HLA-DRB1*04 is a GCA susceptibility allele. The susceptibility data are best explained by amino acid risk residues V, H, and H at positions 11, 13, and 33, contrary to previous suggestions of amino acids in the second hypervariable region. Worldwide, GCA incidence was independently associated both with population frequency of HLA-DRB1*04 and with latitude itself. We conclude that variation in population HLA-DRB1*04 frequency may partly explain variations in GCA incidence and that HLA-DRB1*04 may warrant investigation as a potential prognostic or predictive biomarker. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0692-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4520081
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45200812015-07-31 Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation Mackie, Sarah Louise Taylor, John C. Haroon-Rashid, Lubna Martin, Stephen Dasgupta, Bhaskar Gough, Andrew Green, Michael Hordon, Lesley Jarrett, Stephen Pease, Colin T. Barrett, Jennifer H. Watts, Richard Morgan, Ann W. Arthritis Res Ther Research Article INTRODUCTION: Giant cell arteritis (GCA) is an autoimmune disease commonest in Northern Europe and Scandinavia. Previous studies report various associations with HLA-DRB1*04 and HLA-DRB1*01; HLA-DRB1 alleles show a gradient in population prevalence within Europe. Our aims were (1) to determine which amino acid residues within HLA-DRB1 best explained HLA-DRB1 allele susceptibility and protective effects in GCA, seen in UK data combined in meta-analysis with previously published data, and (2) to determine whether the incidence of GCA in different countries is associated with the population prevalence of the HLA-DRB1 alleles that we identified in our meta-analysis. METHODS: GCA patients from the UK GCA Consortium were genotyped by using single-strand oligonucleotide polymerization, allele-specific polymerase chain reaction, and direct sequencing. Meta-analysis was used to compare and combine our results with published data, and public databases were used to identify amino acid residues that may explain observed susceptibility/protective effects. Finally, we determined the relationship of HLA-DRB1*04 population carrier frequency and latitude to GCA incidence reported in different countries. RESULTS: In our UK data (225 cases and 1378 controls), HLA-DRB1*04 carriage was associated with GCA susceptibility (odds ratio (OR) = 2.69, P = 1.5×10(−11)), but HLA-DRB1*01 was protective (adjusted OR = 0.55, P = 0.0046). In meta-analysis combined with 14 published studies (an additional 691 cases and 4038 controls), protective effects were seen from HLA-DR2, which comprises HLA-DRB1*15 and HLA-DRB1*16 (OR = 0.65, P = 8.2×10(−6)) and possibly from HLA-DRB1*01 (OR = 0.73, P = 0.037). GCA incidence (n = 17 countries) was associated with population HLA-DRB1*04 allele frequency (P = 0.008; adjusted R(2) = 0.51 on univariable analysis, adjusted R(2) = 0.62 after also including latitude); latitude also made an independent contribution. CONCLUSIONS: We confirm that HLA-DRB1*04 is a GCA susceptibility allele. The susceptibility data are best explained by amino acid risk residues V, H, and H at positions 11, 13, and 33, contrary to previous suggestions of amino acids in the second hypervariable region. Worldwide, GCA incidence was independently associated both with population frequency of HLA-DRB1*04 and with latitude itself. We conclude that variation in population HLA-DRB1*04 frequency may partly explain variations in GCA incidence and that HLA-DRB1*04 may warrant investigation as a potential prognostic or predictive biomarker. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0692-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-30 2015 /pmc/articles/PMC4520081/ /pubmed/26223536 http://dx.doi.org/10.1186/s13075-015-0692-4 Text en © Mackie et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise credited.
spellingShingle Research Article
Mackie, Sarah Louise
Taylor, John C.
Haroon-Rashid, Lubna
Martin, Stephen
Dasgupta, Bhaskar
Gough, Andrew
Green, Michael
Hordon, Lesley
Jarrett, Stephen
Pease, Colin T.
Barrett, Jennifer H.
Watts, Richard
Morgan, Ann W.
Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation
title Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation
title_full Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation
title_fullStr Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation
title_full_unstemmed Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation
title_short Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation
title_sort association of hla-drb1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520081/
https://www.ncbi.nlm.nih.gov/pubmed/26223536
http://dx.doi.org/10.1186/s13075-015-0692-4
work_keys_str_mv AT mackiesarahlouise associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT taylorjohnc associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT haroonrashidlubna associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT martinstephen associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT dasguptabhaskar associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT goughandrew associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT greenmichael associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT hordonlesley associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT jarrettstephen associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT peasecolint associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT barrettjenniferh associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT wattsrichard associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT morganannw associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation
AT associationofhladrb1aminoacidresidueswithgiantcellarteritisgeneticassociationstudymetaanalysisandgeoepidemiologicalinvestigation